Personalis/$PSNL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Ticker
$PSNL
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
229
Website
Personalis Metrics
BasicAdvanced
$573M
-
-$1.23
1.87
-
Price and volume
Market cap
$573M
Beta
1.87
52-week high
$7.79
52-week low
$2.81
Average daily volume
1.5M
Financial strength
Current ratio
6.906
Quick ratio
6.579
Long term debt to equity
16.841
Total debt to equity
21.812
Interest coverage (TTM)
-1,560.07%
Profitability
EBITDA (TTM)
-56.392
Gross margin (TTM)
33.30%
Net profit margin (TTM)
-98.10%
Operating margin (TTM)
-78.28%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-17.90%
Return on equity (TTM)
-51.25%
Valuation
Price to revenue (TTM)
5.184
Price to book
2.76
Price to tangible book (TTM)
2.76
Price to free cash flow (TTM)
-9.511
Free cash flow yield (TTM)
-10.51%
Free cash flow per share (TTM)
-68.24%
Growth
Revenue change (TTM)
15.57%
Earnings per share change (TTM)
-34.90%
3-year revenue growth (CAGR)
2.39%
3-year earnings per share growth (CAGR)
-12.32%
What the Analysts think about Personalis
Analyst ratings (Buy, Hold, Sell) for Personalis stock.
Bulls say / Bears say
Personalis secured a $50 million investment from Merck and extended its collaboration with Moderna, enhancing its strategic position in precision oncology. (Personalis Press Release)
Lake Street Capital raised its price target for Personalis to $9.00, citing the successful adoption of its 'Win in MRD' strategy and a promising future trajectory. (Investing.com)
Tempus AI invested over $17 million in Personalis, indicating strong confidence in the company's value and growth potential. (Investing.com)
Personalis reported a projected decline in Q4 2024 revenue to between $15 million and $16 million, primarily due to reduced revenue from key clients Moderna and Natera. (Investing.com)
The company reported a net loss with a negative net margin of 104.52% and a negative return on equity of 66.07% in Q3 2024, indicating ongoing financial challenges. (Techdows News)
Personalis' CFO, Aaron Tachibana, sold 1,307 shares of the company's stock, which could be perceived negatively by investors. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Personalis Financial Performance
Revenues and expenses
Personalis Earnings Performance
Company profitability
Personalis News
AllArticlesVideos
Personalis to Announce Second Quarter 2025 Financial Results
Business Wire·6 days ago
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 week ago
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Personalis stock?
Personalis (PSNL) has a market cap of $573M as of July 28, 2025.
What is the P/E ratio for Personalis stock?
The price to earnings (P/E) ratio for Personalis (PSNL) stock is 0 as of July 28, 2025.
Does Personalis stock pay dividends?
No, Personalis (PSNL) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Personalis dividend payment date?
Personalis (PSNL) stock does not pay dividends to its shareholders.
What is the beta indicator for Personalis?
Personalis (PSNL) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.